Advanced search
1 file | 191.28 KB

Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia

Author
Organization
Abstract
Case We report a case of simultaneous methemoglobinemia and hemolytic anemia, probably related to the use of rasburicase, in a child starting treatment for acute lymphoblastic leukemia (ALL). In addition, the patient developed symptoms of pancreatitis. All complications resolved after 3 days of supportive therapy. Conclusion Although usually well tolerated in pediatrics, physicians prescribing rasburicase should be aware of these possible life-threatening adverse reactions.
Keywords
Hemolytic anemia, Clinical pharmacy, Methemoglobinemia, Pancreatitis, Pediatric hemato-oncology, Rasburicase, HYPERURICEMIA, ALLOPURINOL, MANAGEMENT, LYMPHOMA

Downloads

    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 191.28 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Bauters, Tieneke, Veerle Mondelaers, Hugo Robays, Hans De Wilde, Yves Benoit, and Barbara De Moerloose. 2011. “Methemoglobinemia and Hemolytic Anemia After Rasburicase Administration in a Child with Leukemia.” International Journal of Clinical Pharmacy 33 (1): 58–60.
APA
Bauters, Tieneke, Mondelaers, V., Robays, H., De Wilde, H., Benoit, Y., & De Moerloose, B. (2011). Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 33(1), 58–60.
Vancouver
1.
Bauters T, Mondelaers V, Robays H, De Wilde H, Benoit Y, De Moerloose B. Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. 2011;33(1):58–60.
MLA
Bauters, Tieneke, Veerle Mondelaers, Hugo Robays, et al. “Methemoglobinemia and Hemolytic Anemia After Rasburicase Administration in a Child with Leukemia.” INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 33.1 (2011): 58–60. Print.
@article{2007523,
  abstract     = {Case We report a case of simultaneous methemoglobinemia and hemolytic anemia, probably related to the use of rasburicase, in a child starting treatment for acute lymphoblastic leukemia (ALL). In addition, the patient developed symptoms of pancreatitis. All complications resolved after 3 days of supportive therapy. Conclusion Although usually well tolerated in pediatrics, physicians prescribing rasburicase should be aware of these possible life-threatening adverse reactions.},
  author       = {Bauters, Tieneke and Mondelaers, Veerle and Robays, Hugo and De Wilde, Hans and Benoit, Yves and De Moerloose, Barbara},
  issn         = {2210-7703},
  journal      = {INTERNATIONAL JOURNAL OF CLINICAL PHARMACY},
  keyword      = {Hemolytic anemia,Clinical pharmacy,Methemoglobinemia,Pancreatitis,Pediatric hemato-oncology,Rasburicase,HYPERURICEMIA,ALLOPURINOL,MANAGEMENT,LYMPHOMA},
  language     = {eng},
  number       = {1},
  pages        = {58--60},
  title        = {Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia},
  url          = {http://dx.doi.org/10.1007/s11096-011-9484-3},
  volume       = {33},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: